{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-340271","form_type":"8-K","ticker":"BSEM","cik":"0001658678","company_name":"BioStem Technologies, Inc.","filed_at":"2026-08-07T20:15:17+00:00","discovered_at":"2026-08-07T20:16:06.327099+00:00","generated_at":"2026-08-07T20:16:10.855071+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"BioStem Technologies approved for Nasdaq Capital Market listing; trading starts Aug 7","bullets":["Nasdaq approved BSEM common stock for listing on The Nasdaq Capital Market on Aug 6, 2026.","Trading transitions from OTCQB to Nasdaq effective at market open on Aug 7, 2026; ticker remains BSEM.","No shareholder action required; CEO Jason Matuszewski cites expanded capital access and liquidity.","Company is a regenerative medicine firm focused on perinatal tissue allograft products."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-340271","json":"https://secwatch.observer/filing/0001193125-26-340271.json","markdown":"https://secwatch.observer/filing/0001193125-26-340271.md","text":"https://secwatch.observer/filing/0001193125-26-340271.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1658678/000119312526340271/0001193125-26-340271-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1658678/000119312526340271/bsem-20260806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-07T20:16:10.855071+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}